PARP15 Chemiluminescent Assay Kit
- Known as:
- PARP15 Chemiluminescent Assay Kit
- Catalog number:
- 80567
- Product Quantity:
- 96 reactions
- Category:
- -
- Supplier:
- BPS Bioscience
- Gene target:
- PARP15 Chemiluminescent Assay Kit
Related genes to: PARP15 Chemiluminescent Assay Kit
- Gene:
- PARP15 NIH gene
- Name:
- poly(ADP-ribose) polymerase family member 15
- Previous symbol:
- -
- Synonyms:
- FLJ40597, pART7
- Chromosome:
- 3q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2004-08-25
- Date modifiied:
- 2016-10-05
Related products to: PARP15 Chemiluminescent Assay Kit
Human ELC ELISA KIT 96 TEST
OxiSelect Hydroxyl Radical Antioxidant Capacity (HORAC) Activity Assay, Trial Size
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: PARP15 Chemiluminescent Assay Kit
- Poly(ADP-ribose) polymerase 15 (PARP15) has emerged as a promising yet underexplored target for BRCA-mutated breast cancer. A key strength of this study is the integration of quantum-level density functional theory (DFT) refinement with long-timescale molecular dynamics (MD) validation, an approach rarely applied together for PARP15 inhibitor discovery. Here, an integrated computational workflow combining structure-based virtual screening, DFT optimization, extended MD simulations (500 ns), MM/GBSA binding free energy estimation, and principal component and free energy landscape analyses was employed to identify potential inhibitors of the PARP15 catalytic domain from the Diverse-lib chemical library. Following DFT-based refinement and re-docking, three top-ranked candidates were subjected to long-timescale MD simulations to evaluate dynamic stability. Among them, compound 85267964(4-[2-[4-(3-chloro-4-fluorophenyl)sulfonylpiperazin-1-yl]-2-oxoethyl]-2H-phthalazin-1-one) exhibited comparatively favorable computational performance, characterized by stable RMSD profiles, persistent hydrogen bonding, reduced conformational fluctuations, and the most favorable MM/GBSA binding free energy (ΔG_total = -91.72 ± 9.16 kcal/mol). PCA and free energy landscape analyses further supported the presence of stable low-energy conformational states, and superimposition of MD-derived minima confirmed pose integrity. Overall, this study demonstrates the value of combining quantum chemical refinement with dynamic validation for PARP15 inhibitor prioritization and identifies 85267964 as a computationally prioritized candidate warranting further experimental investigation. - Source: PubMed
Publication date: 2026/06/17
Albadari NajahAlafnan AhmedAlmuhayfir Mohammed AAlsaud Abdulaziz FAlhamzani Ahmed AAljohani Ahmed AAbouzied Amr S - To investigate the association between PARP14 (rs11719086) and PARP15 (rs12489170) gene variants and the risk of male infertility in the North Indian population of Jammu and Kashmir. - Source: PubMed
Publication date: 2026/03/20
Sharma BhawaniShah RuchiShankarayan RajuBhat Ajaz ATanwar MukeshBhat AudeshWakhloo AjayKumar Rakesh - Mono-ADP-ribosylation, a modification of both proteins and nucleic acids, is implicated in innate immunity. Intracellularly, this modification is catalyzed by PARP enzymes, some induced in response to interferons. Mono-ADP-ribosylation is reversed by hydrolases including proteins with macrodomains, which are conserved across all kingdoms of life. Macrodomains encoded by certain positive-sense single-stranded RNA viruses, such as Chikungunya virus and SARS-CoV-2, antagonize host MARylation to enhance viral replication and suppress the immune response. While macrodomain hydrolase activity is essential for CHIKV replication, in SARS-CoV-2 it predominantly contributes to immune evasion, underscoring viral macrodomains as potential antiviral drug targets. Efforts to develop macrodomain inhibitors include computational modeling, crystallography-based methods, and in vitro assays. However, tools to study macrodomain activity directly in cells remain rare. Here, we established a cell-based assay using PARP15 isoform 1, which we found forms nuclear foci dependent on its ADP-ribosyltransferase activity. Enzymatically active macrodomains dissolve these foci, enabling hydrolase activity monitoring in living cells. Using stable cell lines, this system allows the screening of macrodomain inhibitors while simultaneously addressing cell permeability, toxicity, and physiological relevance. Adaptable to various macrodomains, our platform offers a versatile tool to study macrodomain function in living cells, analyzing mutants, and advancing drug discovery efforts. - Source: PubMed
Publication date: 2026/03/12
Knapp SarahWeber VerenaVerheirstraeten MaudSabcheva AniWright TannerHerkens LeaHauser LukasHirschen LeaGolzmann AlexandraLippok BarbaraKrieg SarahFerraris DanaKnapp StefanLadurner Andreas GRossetti GiuliaLüscher BernhardKorn Patricia - A novel library of new indazole-sulfonamides were synthesized by as single step protocol and evaluated their invitro anticancer activity against three breast cancer cell lines viz. MCF-7, MDA-MB-231, and SKBR-3 cell employing Lapatinib as standard reference. Compounds 3f established promising activity against all the three cell lines with an IC value of 10.77 ± 0.31 µM (MCF-7), 10.82 ± 0.47 µM (MDA-MB-231), and 11.10 ± 0.49 µM (SKBR-3). Compound 3d had shown effective activity with an IC value of 11.40 ± 0.53 (MCF-7), 11.25 ± 0.51 (MDA-MB-231), and 12.32 ± 0.33 µM (SKBR-3). Compound 3 h demonstrated potent activity with an IC value of 13.42 ± 0.25 (MCF-7), 12.97 ± 0.23 (MDA-MB-231), and 13.05 ± 0.37 µM (SKBR-3). Additionally, performed molecular docking study against crystal structure of PARP15 to get insights into molecular binding interactions, it accomplished promising docking scores and binding interactions such as H-bond and hydrophobic in support of experimental investigations. - Source: PubMed
Satti Venkata ReddyRaza Mohammad SaimRoshani KmVeeranki Krishna ChaitanyaMondal Tanmoy - Sinonasal tumours are rare entities presenting with non-specific symptoms, therefore being often misinterpreted. The present study aimed to evaluate if the 13-gene DNA Methylation assay for early cancer detection already assessed in the oral cavity, was also useful in nasal cavity tumours. The case series consisted of 93 patients (63 males/30 females), 49 with malignant tumours, 14 with benign/borderline tumours, 34 as control series with 33 inflammatory polyps and one fungus ball. We collected one flocked swab from the lesion and one from the contralateral nasal cavity. All sinonasal cancer cases were evaluated by bisulfite next generation DNA sequencing, investigating the following genes: ZAP70, ITGA4, KIF1A, PARP15, EPHX3, NTM, LRRTM1, FLI1, MIR193, LINC00599, MIR296, TERT, GP1BB. To evaluate the performance of the methylation assay, a specific methylation score was calculated for each sample using linear discriminant analysis, with a predefined positivity threshold of 1.0615547. The association between diagnosis and methylation score positivity was evaluated through Fisher's exact test and calculation of risk ratios with 95% confidence intervals. Additionally, dimensionality reduction techniques were employed to explore the structure of the dataset and assess the ability of methylation profiles to distinguish between different pathological conditions. The 13-gene DNA Methylation scored positive in 42/49 malignant tumours; We included also 14 benign/borderline tumours of which 11 scored positive. Among 33 inflammatory polyps, 24 scored negative, as well as 64/70 normal contralateral mucosa and one fungus ball. Therefore, excluding benign/borderline tumours, the detected sensitivity was 85.7% and specificity 85.6% (AUC: 0.878). - Source: PubMed
Publication date: 2026/01/29
Morandi LucaFarneti PaoloLeucci Anna CaterinaQuerzoli GiuliaMelotti SofiaCamagni AngelaGalli PaoloSollini GiacomoFranchi AlessandroTonon CaterinaLodi RaffaelePasquini ErnestoFoschini Maria Pia